Stratos Wealth Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $892K | Sell |
4,702
-624
| -12% | -$117K | 0.01% | 891 |
|
|
2026
Q1 | $1.05M | Sell |
5,326
-329
| -6% | -$63.4K | 0.01% | 777 |
|
|
2025
Q4 | $1.04M | Buy |
5,655
+581
| +11% | +$102K | 0.01% | 756 |
|
|
2025
Q3 | $779K | Sell |
5,074
-17
| -0.3% | -$2.57K | 0.01% | 850 |
|
|
2025
Q2 | $712K | Sell |
5,091
-185
| -4% | -$25.9K | 0.01% | 812 |
|
|
2025
Q1 | $776K | Sell |
5,276
-1,462
| -22% | -$212K | 0.01% | 743 |
|
|
2024
Q4 | $883K | Sell |
6,738
-418
| -6% | -$58.5K | 0.01% | 738 |
|
|
2024
Q3 | $1.12M | Buy |
7,156
+85
| +1% | +$13.7K | 0.02% | 641 |
|
|
2024
Q2 | $1.1M | Sell |
7,071
-227
| -3% | -$34.2K | 0.02% | 612 |
|
|
2024
Q1 | $989K | Buy |
7,298
+501
| +7% | +$66.3K | 0.02% | 652 |
|
|
2023
Q4 | $916K | Sell |
6,797
-130
| -2% | -$16.9K | 0.02% | 662 |
|
|
2023
Q3 | $938K | Buy |
6,927
+432
| +7% | +$59K | 0.02% | 600 |
|
|
2023
Q2 | $930K | Buy |
6,495
+1,697
| +35% | +$250K | 0.02% | 558 |
|
|
2023
Q1 | $666K | Sell |
4,798
-1,919
| -29% | -$258K | 0.02% | 594 |
|
|
2022
Q4 | $911K | Sell |
6,717
-239
| -3% | -$30K | 0.02% | 534 |
|
|
2022
Q3 | $763K | Sell |
6,956
-535
| -7% | -$67.9K | 0.02% | 558 |
|
|
2022
Q2 | $990K | Sell |
7,491
-1,466
| -16% | -$192K | 0.03% | 519 |
|
|
2022
Q1 | $1.19M | Sell |
8,957
-98
| -1% | -$11.8K | 0.03% | 509 |
|
|
2021
Q4 | $1.05M | Sell |
9,055
-3,007
| -25% | -$354K | 0.02% | 546 |
|
|
2021
Q3 | $1.45M | Sell |
12,062
-313
| -3% | -$36.4K | 0.04% | 418 |
|
|
2021
Q2 | $1.48M | Sell |
12,375
-1,752
| -12% | -$192K | 0.04% | 427 |
|
|
2021
Q1 | $1.41M | Buy |
14,127
+514
| +4% | +$51.7K | 0.04% | 408 |
|
|
2020
Q4 | $1.36M | Buy |
13,613
+8,443
| +163% | +$894K | 0.04% | 367 |
|
|
2020
Q3 | $567K | Sell |
5,170
-119
| -2% | -$13.2K | 0.02% | 579 |
|
|
2020
Q2 | $560K | Buy |
+5,289
| New | +$546K | 0.02% | 559 |
|
|
2018
Q2 | – | Sell |
-2,024
| Closed | -$142K | – | 1096 |
|
|
2018
Q1 | $142K | Buy |
2,024
+159
| +9% | +$11K | 0.01% | 1029 |
|
|
2017
Q4 | $129K | Sell |
1,865
-1,819
| -49% | -$123K | 0.01% | 1050 |
|
|
2017
Q3 | $250K | Buy |
+3,684
| New | +$233K | 0.01% | 763 |
|
|
2014
Q3 | – | Sell |
-11,981
| Closed | -$891K | – | 333 |
|
|
2014
Q2 | $891K | Buy |
+11,981
| New | +$866K | 0.3% | 98 |
|
Other funds holding AZN
EP
IA
Stratos Wealth Partners's AZN Position: Q2 2026 in Review
Stratos Wealth Partners reduced its AstraZeneca (AZN) stake by 12% in Q2 2026, selling an estimated $117K and leaving 4,702 shares worth $892K. The position accounts for 0.01% of the portfolio, ranked #891.
Stratos Wealth Partners first reported a position in AZN in Q2 2014 and has held it in 29 quarters since. The position peaked at $1.48M in Q2 2021. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Stratos Wealth Partners held 4,702 shares of AstraZeneca worth $892K as of Q2 2026.
- Stratos Wealth Partners sold 624 AstraZeneca shares in Q2 2026, an estimated $117K.
- AstraZeneca made up 0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #891 holding.
- Stratos Wealth Partners first reported a position in AstraZeneca in Q2 2014 and has held it in 29 quarters since.
- Stratos Wealth Partners's AstraZeneca position peaked at $1.48M in Q2 2021.
- 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.